Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safe ...

Alzheimer's disease is a neurodegenerative disease characterized by a progressive decline in mental functions and memory loss. Along with frontotemporal dementia and some other neurodegenerative ...

Regulated cell death (RCD) comprises a diverse and expanding set of molecularly defined processes, such as apoptosis, necroptosis, ferroptosis, and ...

Researchers at Toho University have uncovered a previously unrecognized mechanism controlling how dying cells release the ...

A powerful molecular clock calibrated using data on gene activity from thousands of individuals can predicts biological ...

Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions ...

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Treatments aim to bulk up failing hearts to restore their vigour – but can the field move on from past controversy?

A new study led by researchers at the University of California San Diego School of Medicine suggests that an experimental ...